Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Metronidazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 5/20 | 0.62 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.62 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.57 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.55 |
| ▸ | EGFR known ✓ | P00533 | 2/20 | 0.50 |
| ▸ | ERBB2 known ✓ | P04626 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.97 |
| ▸ | THRB | P10828 | 1/20 | 0.97 |
| ▸ | TSHR | P16473 | 1/20 | 0.97 |
| ▸ | CA1 | P00915 | 5/20 | 0.62 |
| ▸ | CA9 | Q16790 | 5/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | CA12 | O43570 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metronidazole SCHEMBL23042 | 0.98 | LMNA (1.00) | LMNAALDH1A1MAPK1THRBTSHR | |
| Metronidazole SCHEMBL5313560 | 0.98 | LMNA (1.00) | LMNAALDH1A1MAPK1THRBTSHR | |
| Metronidazole SCHEMBL9455119 | 0.98 | LMNA (1.00) | LMNAALDH1A1MAPK1THRBTSHR | |
| Metronidazole SCHEMBL9482744 | 0.98 | LMNA (1.00) | LMNAALDH1A1MAPK1THRBTSHR | |
| Metronidazole SCHEMBL2221140 | 0.98 | LMNA (1.00) | LMNAALDH1A1MAPK1THRBTSHR | |
| Metronidazole SCHEMBL9481347 | 0.98 | LMNA (1.00) | LMNAALDH1A1MAPK1THRBTSHR | |
| Metronidazole SCHEMBL31108924 | 0.98 | LMNA (1.00) | LMNAALDH1A1MAPK1THRBTSHR | |
| Metronidazole SCHEMBL5595814 | 0.97 | LMNA (0.97) | LMNAALDH1A1MAPK1THRBTSHR | |
| Metronidazole SCHEMBL3453244 | 0.97 | LMNA (0.97) | LMNAALDH1A1MAPK1THRBTSHR | |
| Metronidazole SCHEMBL8675069 | 0.97 | LMNA (0.97) | LMNAALDH1A1MAPK1THRBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3229 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117384259-A | Cell penetrating peptides based on influenza virus M2 proteins | 中国医学科学院基础医学研究所 | 2024-01-12 | — | — | CN | claimed |
| CN-112912386-B | Cell penetrating peptides based on influenza virus M2 proteins | 中国医学科学院基础医学研究所 | 2023-10-20 | — | — | CN | claimed |
| US-20220169680-A1 | CELL-PENETRATING PEPTIDE BASED ON INFLUENZA VIRUS M2 PROTEIN | INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2022-06-02 | — | — | US | claimed |
| EP-3912989-A1 | CELL-PENETRATING PEPTIDE BASED ON INFLUENZA VIRUS M2 PROTEIN | Institute of Basic Medical Sciences Chinese Academy of Medical Sciences (CN) | 2021-11-24 | — | — | EP | claimed |
| CN-112912386-A | Cell penetrating peptide based on influenza virus M2 protein | 中国医学科学院基础医学研究所 | 2021-06-04 | — | — | CN | claimed |
| WO-2020068665-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2020-04-02 | — | — | WO | claimed |
| CN-109431994-A | Metronidazole injection and its preparation method and application | 江西润泽药业有限公司 | 2019-03-08 | — | — | CN | claimed |
| EP-3400799-A1 | ANTIMICROBIAL IONOMER COMPOSITION AND USES THEREOF | Argenlab Global Ltd (MT) | 2018-11-14 | — | — | EP | claimed |
| EP-2773197-B1 | ANTIMICROBIAL IONOMER COMPOSITION AND USES THEREOF | ARGENLAB GLOBAL LTD (MT) | 2017-10-04 | — | — | EP | claimed |
| US-20170079275-A1 | Antimicrobial ionomer composition and uses thereof | ARGENLAB GLOBAL LTD (MT) | 2017-03-23 | — | — | US | claimed |
| EP-1578434-A2 | METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS | Point Therapeutics, Inc. (US) | 2005-09-28 | — | — | EP | claimed |
| US-20040131628-A1 | Nucleic acids for the treatment of disorders associated with microorganisms | BRATZLER ROBERT L (US) | 2004-07-08 | — | — | US | claimed |
| US-20040077601-A1 | Methods and compositions relating to isoleucine boroproline compounds | POINT THERAPEUTICS, INC. | 2004-04-22 | — | — | US | claimed |
| WO-2004004658-A2 | METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS | POINT THERAPEUTICS, INC. (US) | 2004-01-15 | — | — | WO | claimed |
| EP-1233761-A1 | OSMOTIC DOSAGE FORM COMPRISING FIRST AND SECOND COATS | ALZA Corporation (US) | 2002-08-28 | — | — | EP | claimed |
| EP-0746342-B1 | BIODEGRADABLE CONTROLLED RELEASE MELT-SPUN DELIVERY SYSTEM | BIOVAIL TECH LTD (US) | 2002-08-14 | — | — | EP | claimed |
| WO-2001037815-A1 | OSMOTIC DOSAGE FORM COMPRISING FIRST AND SECOND | ALZA CORPORATION (US) | 2001-05-31 | — | — | WO | claimed |
| US-5948416-A | LEAVE ON SKIN CARE COMPOSITION; HYDROPHOBIC STRUCTURING AGENT; HYDROPHILIC CATIONIC SURFACTANT; ACTIVE COMPOUND | THE PROCTER & GAMBLE COMPANY (US) | 1999-09-07 | — | — | US | claimed |
| US-5891707-A | System for producing Enterocytozoon bieneusi live organisms | SWABBY KENNA DIANE (US) | 1999-04-06 | — | — | US | claimed |
| US-5780049-A | Enhanced skin penetration system for improved topical delivery of drugs | RICHARDSON-VICKS INC. (US) | 1998-07-14 | — | — | US | claimed |